Joas L - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor.

Ma S, Suchomel J, Yanez E, Yost E, Liang X, Zhu R, Le H, Siebers N, Joas L, Morley R, Royer-Joo S, Pirzkall A, Salphati L, Ware JA, Morrissey KM. Ma S, et al. Among authors: joas l. Br J Clin Pharmacol. 2019 Aug;85(8):1751-1760. doi: 10.1111/bcp.13961. Epub 2019 Jun 14. Br J Clin Pharmacol. 2019. PMID: 30973970 Free PMC article. Clinical Trial.

Absorption, metabolism and excretion of pictilisib, a potent pan-class I phosphatidylinositol-3-Kinase (PI3K) inhibitor, in rats, dogs, and humans.

Yue Q, Khojasteh SC, Cho S, Ma S, Mulder T, Chen J, Pang J, Ding X, Deese A, Pellet JD, Siebers N, Joas L, Salphati L, Ware JA. Yue Q, et al. Among authors: joas l. Xenobiotica. 2021 Jul;51(7):796-810. doi: 10.1080/00498254.2021.1923859. Epub 2021 May 24. Xenobiotica. 2021. PMID: 33938357

A better method of quality control for 99mTc-tetrofosmin.

Hammes R, Joas LA, Kirschling TE, Ledford JR, Knox TL, Nybo MR, Sterzinger JJ. Hammes R, et al. Among authors: joas la. J Nucl Med Technol. 2004 Jun;32(2):72-8. J Nucl Med Technol. 2004. PMID: 15175403 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3 results

Search Page